IRCT20140818018842N36招募中1 期
Combinational Cell Therapy using Natural Killer Cells and Erbitux in Patients with Advanced Gastric Adenocarcinoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 60 months（—）
- 性别
- All
入选标准
- •Age between 20 and 60 years- Histologically confirmed adenocarcinoma of the stomach- Patients who have relapsed at least once after gastrectomy and did not respond to chemotherapy.- Patients receiving the same chemotherapy regimen.- Patients with the same tumor size.- Diffuse form of histopathology.- Eastern Cooperative Oncology Group (ECOG) performance status<2- Life expectancy of at least 3 months- Absence of heart problems- Proper functioning of vital organs:leukocyte count =3000/mm3neutrophil count =1500/mm3platelet count =100,000/mm3hemoglobin =9.0 g/dLserum aspartate aminotransferase (AST) =100 IU/Lalanine aminotransferase (ALT) =100 IU/Lserum total bilirubin =2 mg/dLserum creatinine =1.5 mg/dLblood urea =25 mg/d
排除标准
- •- Positive test for HIV, HTLV-1, syphilis, hepatitis B and C infections- Severe active infection- Serious complications such as diabetes mellitus, unstable angina, or myocardial infarction within 3 months- Pregnancy or lactation period- History of autoimmune diseases and hypersensitivity- History of receiving any type of cell therapy in the last 6 months
研究者
相似试验
招募中
Unknown
Cell therapy using natural killer cells pretreatment with Anti-NKG2A in patients with hepatocellular carcinomaIRCT20140818018842N41Tehran University of Medical Sciences3
招募中
1 期
atural Killer cell in acute myeloid leukemiaAcute myeloblastic leukemiaacute myeloid leukemia.C92.0IRCT20140818018842N35Tehran University of Medical Sciences10
招募中
1 期
atural killer cell therapy in acute myeloid leukemia patients patientsAcute myeloid leukemia.Acute myeloblastic leukaemiaC92.0IRCT20230801058996N2Shahid Beheshti University of Medical Sciences15
进行中（未招募）
1 期
Salvage therapy with chemotherapy and Natural Killer cells in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.EUCTR2012-000054-63-ESFUNDACION INVESTIGACION BIOMEDICA HOSPITAL NINO JESUS
尚未招募
不适用
atural Killer cel therapie tegen teruggekeerde eierstokkanker.Recurrent ovarian carcinoma, recidief ovarium carcinoom. immunotherapy, immuuntherapie.NL-OMON20648Radboudumc12